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Abstract
Natural killer (NK) cells recognize and destroy cancer cells through a variety of mechanisms. They
may also modulate the adaptive immune response to cancer by interacting with DCs and T cells.
Although NK cells play an important role in tumor suppression, little is known about the mechanisms
of their recruitment to tumors. Previously it has been shown that subcutaneous tumor growth is
enhanced in mice lacking selectins, a family of cell adhesion molecules that mediate the first step of
immune cell entry into tissue from the blood. Here we demonstrate that NK cell recruitment to tumors
is defective in selectin-deficient mice. In vivo NK cell depletion, either pharmacologic or genetic,
leads to enhanced subcutaneous tumor growth, similar to the phenotype observed in the selectin-
deficient animals. We also show that, although NK cells from selectin-deficient mice appear
developmentally normal, and are functional in in vitro assays, their in vivo function is impaired. This
study reveals a role for selectins in NK cell recruitment to tumors and in regulation of effective tumor
immunity.
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Introduction
Primary tumor growth is a complex process, involving many interactions between the tumor
and surrounding tissue. A developing tumor influences and is influenced by its stroma, initiates
angiogenesis, and interacts with both the adaptive and innate immune systems. The concept of
the immune system surveying the body for nascent tumors and suppressing tumor growth dates
to the beginning of the 20th century. While the immune surveillance hypothesis has had a
turbulent history (1,2), it is now generally accepted that the immune system plays an important
role in controlling cancer progression (1,3-5).
Innate immune cells clearly participate in immune surveillance. There is clinical and
experimental evidence to implicate macrophages (6,7), mast cells (8,9), eosinophils (10),
dendritic cells (DCs) (11) and natural killer (NK) cells (12,13) in tumor interactions. While
many innate immune cells have both tumor-promoting and tumor-suppressive functions (14,
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15), NK cells are generally considered tumor-suppressive (1,16,17). Through a variety of
positive and negative receptors, NK cells can recognize (2,16) and eliminate tumor cells by
several mechanisms (16,18). In addition to their well-known cytotoxic functions, NK cells are
also gaining recognition as key regulators of the adaptive immune response. Several recent
studies indicate that NK cells can activate DCs (19,20) and influence T cell differentiation
(20,21). NK cell-related cancer immunotherapies are being actively investigated (22,23).
Although much progress has been made in understanding the processes of NK cell target
recognition, target killing, and cross-talk with other immune cells, the cell adhesion
mechanisms that mediate NK cell traffic to the tumor are still unclear (24,25). NK cells are not
tissue-resident cells in most organs. However, NK cells need contact with tumor cells in order
to recognize and eliminate them (16). Therefore cell adhesion mechanisms that would allow
NK cells to exit the circulation and enter into tissues must play an important role in NK-
mediated tumor surveillance.
Classical immune cell recruitment requires chemokines, integrins and selectins. Selectins are
members of the C-type lectin family of cell adhesion molecules. E-selectin is expressed on
activated endothelium, P-selectin is rapidly translocated to the cell surface from intracellular
storage granules in activated endothelium and in platelets, and L-selectin is constitutively
expressed on leukocytes. Selectins mediate initial rolling of leukocytes along activated
endothelium, as has been demonstrated for neutrophils, monocytes and T cells (26-28). The
rolling step allows for activation of leukocyte integrins, leading to firm leukocyte adhesion to
endothelium, and subsequent extravasation into tissue (27,28). Selectins are critical for immune
cell trafficking, as revealed by defective leukocyte rolling and recruitment to lymphoid organs
and to sites of inflammation in selectin-deficient mice (29-32). It is known that NK cells express
L-selectin and selectin ligands, and can use them for rolling in in vitro studies (24,25). However,
there is little prior work to indicate whether selectin-dependent recruitment mechanisms are
important for NK cell traffic in vivo.
Previous experiments from our laboratory demonstrated that human tumors injected
subcutaneously into Rag2-/- mice grow significantly larger in the absence than in the presence
of selectins (33). This phenotype is largely transferable with bone marrow transplant. These
results implicated selectins and the innate immune system in tumor immune surveillance. Since
selectins are known to play a role in immune cell traffic, we hypothesized enhanced tumor
growth in the absence of selectins may be due to defective migration of tumor-suppressing
immune cells.
In this paper, we have extended the previous xenograft tumor model to immunocompetent
C57BL/6 mice. In concordance with previous work on human cell lines, we found that several
syngeneic murine tumor cell lines grow significantly better in selectin-deficient mice. We
explored leukocyte traffic in selectin-deficient mice, and discovered that NK cell recruitment
to tumors is impaired in the absence of selectins. NK cells isolated from selectin-deficient mice
appear otherwise normal and functional. In mice depleted of NK cells, either pharmacologically
by antibody injection, or genetically in NK-deficient GrzA-Ly49A transgenic mice (34), tumor
growth is significantly enhanced. Increased tumor growth in the absence of NK cells is not
augmented further by the absence of both NK cells and selectins, arguing that selectins and
NK cells act in the same pathway to suppress tumor growth. Furthermore, the ability of NK
cells to clear tumors in selectin-deficient mice is defective. These results suggest that NK cells
act to suppress tumor growth in our system and depend on selectins to do so.
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Materials and Methods
Mice
Mice missing all combinations of selectins were created in our laboratory (29,31,32) and back-
crossed for 8-9 generations onto C57BL/6, BALB/c, or 129S4 backgrounds. Mice are referred
to by the selectins they are missing: L-/- for L-selectin knockouts, ELP-/- for triple selectin
knockouts. Immune-deficient mice missing the recombination activating gene 2 (Rag2-/-) on
C57BL/6 background were obtained from the laboratory of Dr. Chen (MIT) (35). Mice where
NK cell development is disrupted by the insertion of the Ly49A NK receptor under the control
of the Granzyme A promoter (GrzA-Ly49Atg) backcrossed to the C57BL/6 background were
obtained from the laboratory of Dr. Yokoyama (Washington University St. Louis) (34).
Subcutaneous tumors
For tumor growth assays, B16F0 melanoma, LL/2 Lewis lung carcinoma, and CT26
adenocarcinoma cells were obtained from the American Type Culture Collection (ATCC,
Manassas, VA). MC38GFP colon carcinoma cells were obtained from the laboratory of Dr.
Varki (UCSD) (36). B16-puro and B16-puroRae1ε variants were generated by infecting B16F0
cells with lentiviral vectors containing appropriate constructs (empty vector or vector
containing Rae1ε, respectively). The cells were infected and selected in parallel; Rae1ε
expression was validated by FACS. The Rae1ε construct was a kind gift from Dr. Raulet (UC
Berkeley). All tumor cell lines were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM), 10% heat-inactivated fetal bovine serum (FBS), glutamine and penicillin/
streptomycin (100X stock from Gibco-Invitrogen). For in vivo experiments, anesthetized 8- to
12-week-old mice were injected subcutaneously in the flank with 1×104 tumor cells/mouse in
Hank’s Balanced Salt Solution (HBSS, Gibco-Invitrogen), or in 50% HBSS/50% growth
factor-reduced Matrigel (BD Biosciences) for Matrigel experiments. For time-course
experiments, mice were monitored every 2-3 days by palpation for tumor presence at the
injection site. Tumor surface area was calculated by multiplying the length of the tumor by its
width. For endpoint experiments, tumors were removed and weighed 21 days after tumor cell
injection.
Immune cell purification from Matrigel
Matrigel “plugs” were removed on days 1, 3, 5, 7, and 10 after tumor injection; 4-7 mice of
each genotype (C57BL/6, L-/-, ELP-/-) were analyzed at every time point. The “plug” was
mechanically dissociated and incubated with agitation at 37°C for 2 hours in 0.2% auto-
digested collagenase I (Worthington Biochemical Corporation) in PBS. Digested samples were
strained through a 70μm-mesh sieve. Larger pieces were mashed through the sieve with the
rubber-capped end of a syringe plunger. A 100μL sample was counted by hemocytometer to
establish total cell number in the Matrigel plug. Recovered cells were pelleted by centrifugation
and analyzed by FACS.
Flow cytometry
Cells harvested from Matrigel “plugs” or from mouse tissues were analyzed on a four-color
FACSCalibur (BD Biosciences) flow cytometer supported by FlowJo software. Antibodies
used were against CD3, CD4, CD8, NK1.1, Gr1, CD107a, NKG2D, NKG2A/C/E, Ly49C/I/
F/H, Ly49A/D, MEL14 (L-selectin, CD62L), PSGL-1 (CD162), DX5 (α2 integrin, CD49b),
LFA-1 (αL integrin, CD11a), Mac-1 (αM integrin, CD11b), CD11c (αX integrin), αV integrin,
α5 integrin, and isotype controls (BD Biosciences). Pan-specific anti-mRae1 antibody was
obtained from R&D Systems.
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In vitro cytotoxicity assay
Yac-1 lymphoma cells were obtained from the American Type Culture Collection (ATCC,
Manassas, VA) and cultured in RPMI medium/10% FBS, L-glutamine and penicillin/
streptomycin (100X stock from Gibco-Invitrogen). NK cells were isolated by positive selection
with anti-DX5 beads (Miltenyi Biotech), plated at ∼1×106 NK cells/well, and activated
overnight in complete RPMI medium supplemented with 125U/mL IL-2 (BD Biosciences) and
75ng/mL IL-15 (Sigma). Activated NK cells were co-incubated at varying effector:target ratios
with target cells (1×104 Yac-1 cells/well; 2×103 RMA or LL/2 tumor cells/well) for 4 hours.
Target cell killing was assayed using the CytoTox Non-Radioactive Cytotoxicity assay
(Promega). In L-selectin blocking experiments, NK cells were pre-treated with the L-selectin
blocking antibody MEL14 or an isotype control antibody (BD Biosciences), which were
present throughout the assay.
NK cell interferon γ production and degranulation
Purified splenic NK cells were either left in culture medium (RPMI+5%FBS) alone for 4 or
30 hours, stimulated with LL/2 tumor cells, or stimulated with NK1.1 activating antibody or
an isotype control antibody for 6 hours as described previously (37). Interferon γ (IFNγ)
secretion was assayed using the DuoSet ELISA Development System for IFNγ (R&D
Systems). In some cases, NK cells were recovered after 6-hour stimulation and analyzed by
FACS for surface CD107a expression to assess degranulation in response to activating stimuli.
NK cell antibody depletion
TM-β1 NK-depleting antibody (against mouse IL-2 receptor β) (38) and RR4-7 control
antibody (against human T cell receptor variant) were purified in the laboratory from
hybridoma supernatants. Hybridoma cells were provided by, respectively, Dr. Tanaka (Osaka
University, Japan), and Dr. Eisen (MIT). For NK cell depletion experiments, antibodies were
injected intraperitoneally at 1mg/mouse in 500μL of sterile PBS. Antibody injection was
performed once, 3 days prior to tumor cell injection. The efficiency of NK cell depletion was
monitored throughout the experiment by FACS analysis of small blood samples collected from
the tail vein of antibody-treated mice.
Statistical analysis
All data have been subjected to statistical analysis. For graphic representations, data are
presented as mean values for at least 3 individual experiments with error bars representing
standard error of the mean (SEM). For determining the statistical significance of the differences
in the data, two-tailed Student’s t test analysis with the assumption of unequal variance was
used. In cases where tumor incidence varied, statistical significance was additionally assayed
by a chi2 test. All statistically significant (p<0.05) differences in the data are indicated by
asterisks (*) in the figures.
Results
LL/2 tumor growth is enhanced in selectin-null mice
To investigate the mechanism of selectin-dependent tumor suppression in the context of an
intact immune system, we extended our previous studies to fully murine models, using inbred
mouse strains and subcutaneous injection of syngeneic tumor cell lines. Growth of MC38GFP,
B16F0, and LL/2 cells syngeneic to C57BL/6, as well as CT26 cells syngeneic to BALB/c,
was assayed in selectin-deficient and in control selectin-replete mice (Fig. 1). Tumors were
analyzed at 3 weeks after injection. In all cases, tumors arose more frequently and grew larger
in selectin-deficient mice than in matched selectin-replete controls (Fig. 1). In both C57BL/6
and in BALB/c backgrounds, the tumors were largest and most frequent in ELP-/- mice. Using
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LL/2 cells, which showed the clearest difference in tumor growth between selectin-deficient
and control mice, we further explored tumor growth in mice missing single selectins and in
mice missing both of the endothelial selectins (PE-/-). Of the single selectin knockouts, L-/-
mice were most similar in tumor growth to the triple knockouts, P-/- mice and PE-/- double
knockouts showed a mild tumor enhancement, and E-/- animals showed no tumor growth (Fig.
1D). These findings are consistent with previous data using human cell lines (33), and indicate
that selectin-dependent tumor suppression is an important phenomenon for a variety of tumor
cell lines in multiple mouse strains.
Selectin-deficient mice are defective in NK cell recruitment to tumors
Having established an immune-competent fully murine model, we proceeded to investigate the
causes of the differences in tumor growth. Since selectins are known to be involved in immune
cell recruitment, we hypothesized that selectin-deficient mice fail to reject tumors because
tumoricidal immune cells are unable to reach the tumor. To obtain samples which could be
readily harvested and assayed for immune cell recruitment, tumor cells were injected as a
suspension in Matrigel, a commercial preparation of mouse tumor matrix (39,40). LL/2 cells
embedded in growth-factor-reduced Matrigel were injected into the right flank of selectin-
replete or selectin-deficient mice, while Matrigel alone was injected into the left flank of the
same mice. Matrigel plugs were removed from the mice over a course of 10 days following
injection and analyzed by FACS for immune cell content.
Matrigel enhanced tumor growth in all mice, but differences in tumor size between selectin-
replete and selectin-deficient mice were preserved (Fig. 2A). Analysis of total immune cell
infiltration into Matrigel plugs demonstrated that the overall immune response to tumor-
containing Matrigel was significantly more robust than the immune response to Matrigel alone
(Fig. 2B). Matrigel plugs were assayed for the presence of neutrophils, CD4+ T cells, CD8+ T
cells, macrophages, DCs and NK cells. Neutrophil recruitment proved neither tumor-specific
nor significantly impaired by the absence of selectins. No significant differences in T cell
recruitment were detected between selectin-deficient and control mice. We observed some
reduction in tumor-specific recruitment of macrophages and DCs in selectin-deficient mice
(Supp. Fig. 1). However, since defects in macrophage and DC recruitment were only present
either in ELP-/- or in L-/- mice but not in both, while the tumor growth increase was observed
both in ELP-/- and in L-/- mice, these differences were not pursued further.
Analysis of immune cell content of tumors in Matrigel showed a clear and consistent defect in
tumor-specific NK cell recruitment both in ELP-/- and in L-/- mice. Early NK cell recruitment
to tumors was similar in all mice and independent of tumor cell presence in Matrigel plugs. In
Matrigel plugs without tumor cells, NK cell numbers slowly declined over time in all mice.
However, NK cell recruitment to tumor cell-containing Matrigel plugs increased steadily in
selectin-replete mice, peaking on day 7 after tumor injection. In contrast, NK cell recruitment
to tumors in ELP-/- and L-/- mice was markedly reduced, particularly at the peak of NK cell
infiltration (Fig. 2C).
These data demonstrate, first, that NK cells are recruited to Matrigel plugs containing tumor
cells, but not to Matrigel alone, confirming that NK cell recruitment in our system is not a
general reaction to Matrigel nor to tissue injury caused by the injection, but a tumor cell-specific
response. Second, the results show that NK cell recruitment to tumors is defective in ELP-/-
and L-/- mice. These data establish NK cells as good candidates for mediating selectin-
dependent tumor suppression.
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NK cell development is unimpaired in the absence of selectins
To ascertain that the defect in NK cell recruitment to tumors in selectin-deficient mice is not
due to an overall NK cell deficit in these animals, we performed a comparative analysis of NK
cells from selectin-replete and selectin-deficient mice.
First, we confirmed that NK cells isolated from spleens of C57BL/6 mice express L-selectin
and the main ligand for all three selectins, PSGL-1, as has been reported (24,41-43). We found
that L-selectin is highly expressed on splenic NK cells, while PSGL-1 is expressed at low
levels, and that expression levels of L-selectin and PSGL-1 are not altered by overnight NK
cell activation with cytokines (Fig. 3A). To investigate NK cell development in selectin-
deficient mice, we performed FACS analysis of blood, bone marrow, and lymphoid organs.
NK cells were present in the blood and bone marrow of the ELP-/- and L-/- mice in normal
numbers (Fig. 3B). NK cell numbers in the lymph nodes of L-/- mice were reduced, while NK
cell numbers in the spleens of ELP-/- mice were increased, in keeping with known disturbances
of leukocyte recirculation in these mouse strains (30,32). NK cell receptor repertoire remained
largely unaltered in the absence of selectins (Supp. Fig. 2). We next assayed selectin-deficient
and selectin-replete mice for changes in NK cell integrin expression that are known to correlate
to NK cell developmental stages (44). As with NK cells from selectin-replete animals, integrin
αV was downregulated on NK cells from selectin-deficient mice as the cells exited the bone
marrow, while the expression of integrin αMβ2, which is a marker of mature activated NK
cells, was upregulated (Fig. 3C).
Overall, we did not find any large defects in NK cell number or development in the absence
of selectins. It is therefore unlikely that such disturbances could account for the defect in NK
cell recruitment to tumors in selectin-deficient mice. However, we did confirm that NK cells
normally express L-selectin and a major selectin ligand PSGL-1, which could potentially
contribute to NK cell recruitment to tumors.
Selectin-deficient NK cells retain tumoricidal and secretory functions
To explore whether the inability to reach the tumor was the only functional impairment of
selectin-deficient NK cells, we assayed their ability to kill tumor targets and secrete cytokines
in response to stimulation in vitro. NK cells from ELP-/- and L-/- mice were as efficient as
control NK cells at destroying Yac-1 and RMA tumor targets (Fig. 4A, B). Similarly, when L-
selectin was blocked acutely using the MEL14 antibody, no defects were observed in NK cell
killing of LL/2 targets (Fig. 4C). NK cells are one of the major secretors of the tumor-
suppressing cytokine IFNγ (16, 45). We tested NK cells isolated from spleens of selectin-
deficient mice for their ability to produce IFNγ in response to stimulation. Selectin-deficient
NK cells did not differ significantly from selectin-replete counterparts in IFNγ production in
response to LL/2 tumor cell stimulation or to NK1.1 antibody crosslinking of an activating NK
receptor (Fig. 4D, left panel). Selectin-deficient NK cells also displayed enhanced
degranulation in response to both activating stimuli (Fig. 4D, right panel). In summary, NK
cells from selectin-deficient mice appear functional, apart from the in vivo defect in recruitment
to tumors.
Subcutaneous tumor growth is enhanced in the absence of NK cells
To test whether loss of NK cells contributes to increased tumor growth, we removed NK cells
by two independent methods. Mice were injected with TM-β1 antibody that selectively depletes
NK cells for up to 3 weeks (38), or a control RR4-7 antibody of the same isotype that is
unreactive to mouse antigens. In a parallel set of experiments, we used GrzA-Ly49A transgenic
mice that genetically lack functional NK cells (34,46). NK depletion by either method was
confirmed by monitoring NK cell numbers in the blood (Fig. 5A, B). The antibody depletion
was thorough and stable, while a few NK cells were detected in GrzA-Ly49Atg+ mice.
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However, these cells are reportedly immature and of low cytotoxic potential (34,46). We then
implanted subcutaneous LL/2 tumors into mice lacking NK cells. Depletion of NK cells, either
by antibody or genetically, led to significantly enhanced subcutaneous tumor growth in NK-
depleted animals as compared with matched controls (Fig. 5C).
We next wanted to know whether removing NK cells could explain the increased tumor growth
in selectin-deficient mice. We therefore depleted NK cells in selectin-deficient mice and
monitored tumor growth. Depletion of NK cells from L-/- mice with the TM-β1 antibody did
not result in any synergistic enhancement of tumor growth; nor did tumors grow better in
ELP-/- GrzA-Ly49Atg+ mice than in ELP-/- animals (Fig. 5D). Therefore, it is likely that the
defect in tumor rejection that we observed in selectin-deficient mice is due to a defect in NK
cell recruitment. To test whether loss of adaptive immune cells also affects tumor growth in
selectin-deficient mice, we repeated the LL/2 tumor growth experiments in Rag2-/- and
ELP-/- Rag2-/- mice. In contrast to our results with NK cell depletion, the absence of T, B and
NKT cells did not promote tumor growth in control mice and slightly decreased tumor
incidence in selectin-deficient mice (Fig. 5E).
NK cell depletion had a similar effect on tumor growth to that seen with loss of selectins.
Furthermore, depletion of NK cells from selectin-deficient mice had no additional effect on
tumor growth, showing that NK cells are unable to participate in tumor rejection in selectin-
null mice, while they do so in selectin-replete controls. This indicates that NK cells are
necessary for tumor rejection, and may require selectins in order to function in anti-tumor
immunity. The adaptive immune system does not appear to participate in tumor rejection in
our system.
NK-mediated tumor rejection in vivo requires selectins
To test whether selectins are required for NK cell-mediated tumor rejection, we used a tumor
rejection model that is strongly dependent on NK cells. The B16 C57BL/6 melanoma cell line
does not express NK cell ligands and is fairly resistant to NK cell killing. However, B16 cells
transfected with Rae1, a ligand to an activating NK cell receptor, NKG2D, are rejected
specifically by NK cells (12). We generated matched B16 cell lines to test NK cell function
in vivo: a control cell line (B16-puro) and a cell line stably expressing Rae1ε (B16-Rae1ε).
Rae1ε expression in the matched cell lines was confirmed by FACS analysis (Fig. 6A).
When injected into control mice, B16-puro cells grew sizeable tumors in all animals, while
B16-Rae1ε cells were completely rejected, as expected. Also, as previously reported (12),
rejection was NK cell-specific, since both cell lines gave rise to tumors in GrzA-Ly49Atg+
mice or in mice treated with the TM-β1 antibody (Fig. 6A). When injected into ELP-/- mice,
however, B16-Rae1ε tumors were not rejected (18/18 mice). These results demonstrate a
profound defect in NK cell-mediated tumor rejection in selectin-deficient mice (Fig. 6B). Of
the single selectin knockouts, L-/- mice and P-/- mice displayed partial defects in B16-Rae1ε
tumor rejection, while E-/- mice did not show a significant defect.
These data confirm that selectin-deficient mice have a clear defect in NK-mediated tumor
rejection in vivo. They also demonstrate that both L-selectin and P-selectin contribute to NK
cell anti-tumor function in vivo, while E-selectin does not contribute significantly.
Discussion
In this study we used subcutaneous tumor models to explore the role of selectins in tumor
surveillance by innate immune cells. Existing evidence indicated that, in the absence of
selectins, subcutaneous growth of human tumor cell lines in Rag2-/- mice is enhanced, and that
the innate immune system is likely responsible for selectin-dependent tumor suppression
Sobolev et al. Page 7
Cancer Res. Author manuscript; available in PMC 2009 September 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(33). Here we report increased growth of several syngeneic tumor cell lines of different origins
in selectin-deficient mice, on several genetic backgrounds, confirming that selectin-dependent
tumor suppression is a reproducible and important phenomenon. This phenotype was most
apparent in the absence of all three selectins. Of the single selectin knockouts, L-selectin
contributed most to tumor suppression, P-selectin contributed somewhat, and E-selectin did
not contribute significantly. The predominant role of L-selectin in tumor suppression suggested
that leukocytes are the key mediators of the observed phenotype.
Selectins play a role in immune cell recruitment to tissues and to lymphoid organs. Exploration
of immune cell recruitment to Matrigel-embedded tumors in selectin-deficient mice led to
several important findings. First, we established that all mice, regardless of the presence or
absence of selectins, exhibited a tumor-specific immune response. Second, we found fewer
macrophages, DCs and NK cells recruited to tumors in the absence of selectins. The defect in
NK cell recruitment in the absence of all three selectins, or of L-selectin alone, was particularly
striking. To explore the possibility that other aspects of NK cell biology are also affected in
the absence of selectins, we confirmed that NK cells are present in selectin-deficient mice in
normal numbers, appear to develop normally, and to be functional in in vitro anti-tumor
cytotoxicity and in cytokine secretion assays. Since NK cells are known to be tumoricidal,
seemed normal in the absence of selectins, but failed to infiltrate tumors in selectin-deficient
mice, they became our top candidates for mediating selectin-dependent tumor suppression.
NK cells proved essential for tumor suppression in our system, as growth of several
subcutaneously injected tumor cell lines was enhanced in two different NK cell-deficient
mouse models. In contrast, the adaptive immune system did not actively promote tumor
immunity. Tumor growth in Rag2-/- mice lacking B, T and NKT cells was, if anything, slightly
inhibited. The slight inhibition of tumor growth in Rag2-/- animals could be due to several
factors, including increased NK cell numbers in Rag2-/- mice, and lack of regulatory T cells,
which could normally act to suppress tumor immunity and have recently been shown to
suppress NK cell function (47). To test directly the function of NK cells in selectin-deficient
mice, we used a subcutaneous tumor model where tumor rejection is strongly dependent on
NK cells. Selectin-deficient mice demonstrated a severe defect in NK cell-dependent
elimination of tumor targets in vivo, establishing that selectins are necessary for this process.
Taken together, our data provide evidence that selectins are necessary for tumor elimination;
that NK cells are necessary for tumor elimination; and that NK cells require selectins to clear
tumor targets in vivo. We also found that, in the absence of selectins, NK cells are defective in
entering the tumor. The simplest model suggested by these findings is that in our system NK
cells require selectins, particularly L-selectin, and selectin ligands in order to interact with
tumor vasculature, enter the tumor, and promote its rejection. Our findings support and extend
previous reports, in which it has been demonstrated that in L-selectin-deficient mice, NK cell
numbers around primary or metastatic tumors are reduced (48).
The work described here leaves some open questions. One important caveat to the proposed
model is that it is unclear whether the defect in NK cell function observed in selectin-deficient
mice is cell-intrinsic, or partly attributable to defects in other selectin-dependent cell(s) that
regulate NK cell recruitment or function. NK cells are not the only innate immune cell type
affected by the absence of selectins, as we also observed some defects in tumor-specific
recruitment of macrophages and DCs in selectin-deficient mice. Thus, NK cells and their
recruitment are necessary but may not be sufficient to explain selectin-dependent tumor
suppression.
In addition, it is worth noting that while tumor growth seemed to be strongly dependent on NK
cells in our system, other immune cells may be more important in different tumor models.
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Several factors could influence the immune response to tumors in our model. First, we inject
fully transformed tumor cells, in a procedure that is concomitant with some tissue damage. A
naturally arising tumor that proceeds through all stages of transformation in vivo may well
interact differently with its microenvironment and with the immune system than our tumor
model does. Second, tumor growth in our system is assayed on the timescale of 3 weeks, which
is a relatively short period. NK cells are an early-response immune cell; it is possible that in
models where tumor growth is slower the adaptive immune response would have time to
develop and would contribute to tumor rejection. Lastly, the location and anatomical origin of
the tumor may influence the immune response to that tumor. Nonetheless, our results clearly
demonstrate an important contribution of selectins and NK cells to tumor rejection. It would
therefore be interesting to address the role of NK cells and selectins in spontaneous tumor
models.
Furthermore, selectins are likely not the only adhesion molecules that are required for NK cell
migration to the tumor. Chemokines and chemokine receptors, as well as integrins, may also
be necessary. Of the chemokines, CX3C chemokine (fractalkine) and its receptor CX3CR1
have been implicated in NK cell recruitment to tumors (49). Of the integrins, one publication
associated αLβ2 and αMβ2 integrins with NK cell tumor migration (48). Previous work from
our laboratory also implicates αVβ3 and αVβ5 integrins in tumor suppression (33). It will be
interesting to investigate the contribution of other adhesion molecules to tumor surveillance
by NK cells.
Lastly, L-selectin is also important for immune cell traffic to lymphoid organs. Our findings
do not address this aspect of NK cell migration, but it has been reported that NK cells can use
L-selectin to enter lymph nodes in cancer (50). Although the main proposed role for NK cells
at the lymph node is in regulating the adaptive immune response, and the adaptive immune
system does not appear to control tumor rejection in our system, we cannot rule out the
possibility that defects in NK cell traffic to lymphoid organs may play a role in tumor
overgrowth in selectin-deficient mice.
The results reported here contribute towards a more complete understanding of tumor
immunology, particularly in the poorly understood areas of immune cell migration in cancer
and of innate immune response to cancer. We have examined the role of one family of adhesion
molecules, the selectins, in mouse models of tumorigenesis, and determined that selectins
promote tumor immune surveillance in our experimental system. We have also uncovered some
of the mechanisms by which selectins control tumor growth by demonstrating that NK cell
recruitment and in vivo tumor-suppressive functions are defective in the absence of selectins.
These results strongly implicate selectin-mediated recruitment of NK cells in tumor
surveillance. Understanding the migration and recruitment mechanisms of immune cells in
cancer, while challenging, is both scientifically interesting and potentially clinically valuable,
raising the possibility of targeting the immune response specifically to the tumor.
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Figure 1. Syngeneic subcutaneous tumor growth is increased in the absence of selectins
5×104 MC38GFP colon carcinoma (A) or 1×104 B16F0 melanoma (B) syngeneic to C57BL/
6, 1×104 CT26 colon carcinoma syngeneic to Balb/c (C), or 1×104 Lewis lung carcinoma (LL/
2) syngeneic to C57BL/6 (D), cells were injected subcutaneously into the flank of either control
mice or mice lacking selectins. Three weeks after injection, tumors were dissected out and
weighed. Where dissection was difficult, tumor growth was assayed by measuring tumor
surface area instead of weight (B). Tumor incidence is reported as % mice with tumors out of
total mice of the given genotype that were assayed (n). The weights or sizes of the tumors are
displayed as box-whisker plots, the central line denoting the mean, the shaded gray boxes and
the lines denoting the 90th, 75th, 25th, and 10th percentiles.
*, p<0.05 by two-tailed Student’s t test
**, p<0.0005 two-tailed Student’s t test and p<0.005 by chi2 analysis
Sobolev et al. Page 13
Cancer Res. Author manuscript; available in PMC 2009 September 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2. Selectin-null mice are defective in NK cell recruitment to tumors in Matrigel
1×104 LL/2 cells in 200μL of Matrigel were injected subcutaneously into the right flank of
either C57BL/6 w.t. mice or C57BL/6 selectin-deficient mice. A. Tumors were dissected and
weighed three weeks after injection. Results are expressed as box-whisker plots, the central
line denoting the mean, the shaded gray boxes and the lines denoting the 90th, 75th, 25th, and
10th percentiles. B. Tumors were dissected over a 10-day period after injection, dissociated
into a single-cell suspension, and analyzed by FACS for immune cell content. A plug of
200μL of Matrigel alone injected into the left flank of the same mice at the time of tumor
injection was used as an internal control. Total leukocyte counts in the plugs of C57BL/6
control animals established that the tumor-specific immune response was particularly
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prominent on day 7 after tumor injection. C. At day 7 after tumor injection, NK cell recruitment
to Matrigel containing LL/2 tumor cells, but not to Matrigel alone, was significantly reduced
in L-/- and ELP-/- mice compared with C57BL/6 w.t. controls. NK cells were defined as
NK1.1+, CD4 and CD8- live leukocytes. Results are expressed as mean leukocyte counts
obtained from 5-10 individual animals of each genotype, error bars = SEM.
*, p<0.005 by two-tailed Student’s t test.
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Figure 3. NK cells are developmentally normal in the absence of selectins
A. NK cells were isolated from spleens of C57BL/6 wt mice and either assayed directly or
cultured overnight in activating medium containing IL-2 and IL-15. C57BL/6 NK cells were
analyzed by FACS for expression of L-selectin and selectin ligand PSGL-1. B. NK cell
numbers in blood (∼100μL), bone marrow (1 femur), lymph node (1 inguinal) and spleen of
selectin-replete and selectin-deficient mice were determined from total cell number in the
abovementioned tissues multiplied by percentage of NK1.1+, CD3- cells as determined by
FACS. Data were obtained from at least 3 mice of each genotype and are presented as average
cell numbers ± SEM; statistical significance for selectin-deficient mice as compared to selectin-
replete mice within each organ has been calculated; *, p<0.05 by two-tailed Student’s t test.
C. Freshly isolated blood and bone marrow collected from C57BL/6 selectin-replete and
selectin-deficient mice were analyzed by FACS for expression of αV integrin and CD11b
(Mac-1; αMβ2 integrin). As expected, αV integrin expression decreases on blood NK cells as
compared with the immature NK cells in the bone marrow, while CD11b expression increases.
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Figure 4. NK cells from selectin-deficient mice are functional in vitro
A, B. NK cells were isolated from spleens of selectin-deficient and control C57BL/6 mice.
Purified NK cells were co-cultured with varying ratios of tumor target cells in a standard
cytotoxicity assay. Cytotoxicity of either freshly isolated NK cells (A, left panel) or NK cells
activated overnight in medium containing IL-2 and IL-15 (A, right panel; B, C) was
determined. Target killing was measured using the Promega CytoTox 96® Non-Radioactive
Cytotoxicity Assay. NK cells from selectin-deficient mice (A, B), as well as NK cells treated
with L-selectin-blocking antibody MEL14 or an isotype control antibody prior to and during
the assay (C), displayed normal ability to kill tumor targets. D, left panel: IFNγ secretion by
purified control and selectin-deficient NK cells was assayed by ELISA. NK cells were either
left in culture medium with no additional stimulation for 4hrs. after isolation, stimulated by
co-culture with LL/2 tumor cells for 6hrs, stimulated by NK1.1 antibody or an isotype control
antibody for 6hrs, or allowed to remain in culture medium for 30hrs. Data are normalized to
IFNγ secretion by control NK cells cultured with medium alone for 4hrs. Selectin-deficient
NK cells do not demonstrate any statistically significant differences from selectin-replete
C57BL/6 NK cells within each group. D, right panel: in addition, NK cells stimulated by LL/
2 tumor cells or by the NK1.1 antibody for 6hrs. were assayed for degranulation by CD107a
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FACS analysis. All analyses were performed for at least 3 animals of each genotype. Results
are expressed as bar and line graphs, error bars = SEM
*, p<0.05 by two-tailed Student’s t test.
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Figure 5. NK cells, but not adaptive immune cells, suppress subcutaneous tumor growth
A. As measured by the % NK1.1+/CD3- cells in the blood, mice injected with TM-β1 NK-
depleting antibody (1 mg/mouse i.p.) selectively lose NK cells but not macrophages as
compared with mice treated with the same dose of an isotype control antibody. NK cell numbers
decrease from 3*106 circulating NK cells/mouse on day 0 to 1.2*106 NK cells on day 3 to
6*104 NK cells by day 10 after antibody treatment. B. Similarly, Ly49A-GrzAtg+ mice that
are genetically deficient in NK cells, as compared with tg- littermates, remain depleted of NK
cells (∼5*105 circulating NK cells/mouse) even after 3 weeks of tumor challenge, while T cells
are unaffected. Results are expressed as % NK cells in NK-depleted animals as compared with
the appropriate controls ± SEM. Tumor weight was assayed 3 weeks after injection of 1×104
LL/2 cells into: C. C57BL/6 mice depleted of NK cells, either pharmacologically by TM-β1
antibody injection 3 days prior to tumor cell transfer, or genetically in Ly49tg+ mice; D.
selectin-deficient mice depleted of NK cells; or E. lacking the adaptive immune system
(Rag2-/-). Tumor incidence is reported as % mice with tumors out of total mice of the given
genotype that were assayed (n). The weights or sizes of these tumors that grew are displayed
as box-whisker plots, the central line denoting the mean, the shaded gray boxes and the lines
denoting the 90th, 75th, 25th, and 10th percentiles; plotted below are the corresponding tumor
incidences.
*, p<0.05 by two-tailed Student’s t test.
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Figure 6. Selectin-deficient NK cells are defective in tumor target cell rejection in vivo
A. Inset: B16F0 tumor cells were stably infected with either a construct carrying the Rae1ε
NK cell-activating antigen (B16-Rae1ε cells) or with a vector control (B16-puro cells).
Rae1ε antigen expression was confirmed by FACS. 1×104 B16-Rae1ε or B16-puro cells were
injected s.c. into mice treated with control or NK-depleting TM-β1 antibody, or into Ly49A-
GrzAtg+ and control tg- animals. Tumor growth was assayed by measuring tumor length (L)
and width (W) with calipers every other day and multiplying the values together to obtain tumor
surface area (L*W=surface area, mm2). B. 1×104 B16-Rae1ε or B16-puro cells were injected
s.c. into selectin-deficient mice. Boxed numbers indicate number of mice that developed a
tumor out of the total number of mice assayed. Results are expressed as line graphs of mean
tumor surface area of 5-18 individual mice, error bars = SEM
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